Company Update

May 2015
 FORWARD-LOOKING STATEMENTS

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION

Certain statements and information in this presentation may be deemed to be forward-looking statements within the meaning of the Federal
Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our 2015
Adjusted EBITDA and Adjusted EPS guidance, objectives, plans and strategies, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future, including EVHCs
ability to successfully complete any pending acquisitions, annualized revenue contribution from recent acquisitions and annual estimated patient
encounters from recent acquisitions. Any forward-looking statements herein are made as of the date of this presentation, and we undertake no
duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking
statements are described in our filings with the Securities and Exchange Commission from time to time, including in the section entitled Risk
Factors in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q . Among the factors that could cause future results to differ
materially from those provided in this presentation are: decreases in our revenue and profit margin under our fee-for-service contracts due to
changes in volume, payor mix and third party reimbursement rates, including from political discord in the federal budgeting process; the loss of
existing contracts; failure to accurately assess costs under new contracts; difficulties in our ability to recruit and retain qualified physicians and
other healthcare professionals, and enforce our non-compete agreements with our physicians; failure to implement some or all of our business
strategies, including our efforts to grow our Evolution Health business and cross-sell our services; lawsuits for which we are not fully reserved; the
adequacy of our insurance coverage and insurance reserves; our ability to successfully integrate strategic acquisitions; the high level of
competition in the markets we serve; the cost of capital expenditures to maintain and upgrade our vehicle fleet and medical equipment; the loss of
one or more members of our senior management team; our ability to maintain or implement complex information systems; disruptions in disaster
recovery systems , management continuity planning, or information systems; our ability to adequately protect our intellectual property and other
proprietary rights or to defend against intellectual property infringement claims; challenges by tax authorities on our treatment of certain physicians
as independent contractors; the impact of labor union representation; the impact of fluctuations in results due to our national contract with FEMA;
potential penalties or changes to our operations, including our ability to collect accounts receivable, if we fail to comply with extensive and complex
government regulation of our industry; the impact of changes in the healthcare industry, including changes due to healthcare reform; our ability to
timely enroll our providers in the Medicare program; our ability to restructure our operations to comply with future changes in government
regulation; the outcome of government investigations of certain of our business practices; our ability to comply with the terms of our settlement
agreements with the government; our ability to generate cash flow to service our substantial debt obligations; and other factors discussed in our
filings with the Securities and Exchange Commission.

2
 NON-GAAP FINANCIAL MEASURES

NON-GAAP FINANCIAL MEASURES

In this presentation, we refer to Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted EPS, which are not financial measures calculated and
presented in accordance with generally accepted accounting principles in the United States of America (GAAP). Adjusted EBITDA is defined as
net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other
income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, transaction costs
related to acquisition activities, related party management fees, restructuring charges, severance and related costs, adjustment to net loss
(income) attributable to non-controlling interest due to deferred taxes, and depreciation and amortization expense. Adjusted EBITDA Margin
represents Adjusted EBITDA divided by net revenue. Adjusted EPS is defined as diluted earnings per share adjusted for expenses related to
EVHCs secondary offerings, amortization expense, equity-based compensation expense, restructuring charges and loss on early debt
extinguishment, net of an estimated tax benefit. Adjusted EBITDA for the quarter ended March 31, 2014, has been presented to conform to the
current-period presentation by including transaction costs related to acquisition activity in the definition of Adjusted EBITDA.

These non-GAAP financial measures are commonly used by management and investors as performance measures and liquidity indicators.
However, the items excluded from these non-GAAP financial measures are significant components in understanding and assessing the
Companys financial performance, and as a result, these measures should not be considered in isolation or as an alternative to GAAP measures
such as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the
Companys consolidated financial statements as an indicator of financial performance or liquidity. Since these non-GAAP financial measures are
not measures determined in accordance with GAAP and are susceptible to varying calculations, these measures, as presented, may not be
comparable to other similarly titled measures of other companies. Reconciliations of Adjusted EBITDA to net income for the periods presented are
included in Supplemental Materials presented herein. Reconciliations for the forward-looking full-year 2015 Adjusted EBITDA and Adjusted EPS
projections presented in this presentation are not being provided due to the number of variables in the projected full-year 2015 Adjusted EBITDA
and Adjusted EPS ranges and thus EVHC does not currently have sufficient data to accurately estimate the individual adjustments for such
reconciliations. All comparisons included in this presentation are for the first quarter of 2015 to the comparable 2014 period, unless otherwise
noted.

3
KEY HIGHLIGHTS
Net Revenue ($ in billions) Highlights

Envision
Strong Growth: Q1 2015 revenue up 23%; Adjusted EBITDA up 16%
Organic growth, including increased level of contract starts, driven by customer
demand for differentiated services
Improved capital structure with sufficient liquidity to pursue strategic acquisitions

$4.2 Completed acquisitions of Scottsdale Emergency Associates, VISTA Staffing and

$3.7 Emergency Medical Associates in Q1 15
$3.3
EmCare
Continued strong growth; Q1 2015 revenue up 28.0%
2012 2013 2014 Organic growth continues to be predominantly driven by net new contracts
Robust contract pipeline with strong visibility
Adjusted EBITDA ($ in millions)
AMR
Q1 2015 revenue up 13.5%
Continued execution on cost and productivity initiatives driving margin improvements

$556.2 Entered a definitive agreement to acquire ambulance operations in northeastern U.S.

$455.4 (a) with expected annual revenues of $25M
$9.7
Evolution Health
$445.7
$404.5 Q1 2015 launched joint venture with Ascension Health
2014 completed agreements with Memorial Hermann Health System, Universal
2012 2013 2014 Health Services and Aetna for transitional services and a risk-based contract with
Note: Adjusted EBITDA as defined in Non-GAAP Financial Measures. Prior periods Healthspring in Dallas area
have been adjusted accordingly for comparability purposes. See reconciliation
in supplemental materials.
(a) $9.7M of insurance reserve adjustments for two significantly higher than
expected malpractice cases from 2009 and 2011
4
 PROVEN TRACK RECORD OF EVOLVING THE
BUSINESS TO MEET CUSTOMER AND MARKET NEEDS

2005 2010 2010 2014 2015 Future

2005 Adj. EBITDA: $46M 2014 Adj. EBITDA: $363M

30% 35%

70% 65%

2005 Adj. EBITDA: $106M 2014 Adj. EBITDA: $193M

2005 EBITDA: $152M 2014 EBITDA: $556M

Leading player focused on episodic care
Track record of strong organic growth
Outsized returns delivered to shareholders
through public markets
Accelerated EmCare growth via service line
expansion and integration of services
Re-aligned AMR to drive new revenue
opportunities and improved margins
Expanded service solutions to improve quality
and lower costs
Extended clinical capabilities outside the
hospital through Evolution Health
Positioned for population health management
in the evolving healthcare landscape

History of Successfully Evolving the Business Model Within a Dynamic Healthcare Environment
Note: Adjusted EBITDA as defined in Non-GAAP Financial Measures. Prior periods have been adjusted accordingly for comparability purposes.
See reconciliation in supplemental materials.
5
 POSITIONED AT THE NEXUS OF THE EVOLVING LANDSCAPE
Envision Customers Changing Market Dynamics

Communities
Healthcare reform driving new models of
delivery and reimbursement
Healthcare
Payors
Facilities

Population health driving changes in

managing care across the patient continuum
Key Customer Challenges Addressed by Envision
Value-based Integrated care models improve
Service, quality and patient outcomes
outcomes, reduce cost
Operational expertise / innovation
Movement toward market centricity (space
Recruitment and retention
and scale)
Care coordination at lower costs

Accountability and value based care

Envision is Well-Positioned to Meet the Changing Market Environment and Deliver a

Differentiated Solution for Improving Quality and Lowering the Cost of Care

6
 MULTIPLE LEVERS TO DRIVE STRONG AND
CONSISTENT GROWTH
Organic Growth
Net New
Same Store
Contracts
Consistent underlying Integrated services / cross-
market volume trends selling
Proven track record
improving quality and
Stable pricing and
operating efficiency
reimbursement dynamics
In 2014, 63% of EmCare
Long-term customer new contracts were with
relationships new facilities; 37% were
new services with existing
facilities
AMR experiencing highest
contract win rate in years
Majority of Historical Revenue Growth
Driven by Organic Activity
Proven Track Record of Delivering Strong Growth Through a Combination of New Contracts,
Same-Contract Revenue Growth and Disciplined Value-Enhancing Acquisitions
7
Acquisitions and New Services
Existing
New Services
Services
Highly fragmented Continued development of
markets with only a few additional services that
national providers enhance the patient
continuum
Geographic platform
extensions to enhance Either de novo or through
organic growth acquisitions
Expansion of existing
markets with synergy
opportunities
Acquisition Activity Has Significantly
Expanded Service Offerings
 EMCARE: ROBUST GROWTH PLATFORM WITH
SIGNIFICANT MOMENTUM

EmCare Revenue Growth Breakdown1 EmCare Key Growth Drivers

Acquisitions
Net New Contracts Integrated Services and Cross-Selling
Organic
Same Store Contracts 28.0 %

23.2 %
Expansion of Multiple Service Lines

20.5 % 13.3 %
7.7 % Creative Healthcare System Partnership Models
3.2 %
14.9 %
1.9 %
Share Gains from Local and Regional Groups
12.9 %
10.1 %
8.0 % 13.7 %
Continued Healthcare Facility Outsourcing

5.0 % 4.4 % 4.6 %

1.8 %
2012 2013 2014 Q1 2015
Organic Growth
Robust Contract Pipeline with Strong Visibility
13.0% 15.5% 17.3% 14.7%

Long-Term History of Highly Visible, Recurring Revenue with Recent Acceleration in Growth
1. EmCare net new contract growth in 2012 of 9.9% includes acquisition growth contribution of 1.9%. Same store contracts growth shown above is calculated using total
contracts as the denominator. When calculating net revenue growth contribution from same-store contracts using only contracts in existence for the entirety of both
year-over-year periods in the denominator, 2012 same store contract growth was 6.3%, 2013 was 2.4%, 2014 was 5.5% and 1Q 2015 was 5.0%.
8
AMR: LEADING OUTSOURCED PROVIDER OF
COMMUNITY-BASED MEDICAL TRANSPORTATION SERVICES

AMR Market Size and Positioning1

Ambulance Managed Transportation Fixed-Wing Air Transport2

$18bn $2bn $3bn

7% 4%
AMR Competitive Advantages

Substantial scale advantages in ambulance services Strong brand recognition and national contracting
(more than 2x nearest competitor) capabilities

AMR Medicine drives best of class clinical Managed transportation service offering
outcomes and improved patient experience
Technology investments

Clear Leader in Ambulance Market with Growing Positions in Complementary Service Lines
1. Management estimates of 2014 market size and AMR outsourced market position.
2. Envision outsourced market share represents fixed-wing market only (total market size represents all air medical transportation services).
9
AMR: BUSINESS REALIGNMENT ACCELERATED
GROWTH, LED TO MARGIN IMPROVEMENTS

Positioned for Accelerated Revenue Growth Cost and Productivity Initiatives

Implemented Platform for Sustainable Growth (PSG) in
Strengthened AMR Management Team 2012; key initiatives to date include:
Rationalization of underperforming contracts
Proven Superior Clinical Outcomes (AMR Medicine) Organizational and infrastructure realignment
Support function efficiencies
Increasing New Contract Win Rates
AMR Adjusted EBITDA Margin Improvement Since 2010

Expanding Complementary Service Offerings 300bps 12.4%

9.4%

Strong Financial Position vs. Competitors

Emerging Product Lines Across Patient Continuum

2010 2014

Achieved Q1 2015 Revenue Growth of 13.5% over Q1 2014 Future AMR Margin Improvements Primarily
Driven by Technology Investments

Well-Positioned for Accelerated Revenue Growth and Continued Margin Improvements

Note: Adjusted EBITDA as defined in Non-GAAP Financial Measures. See reconciliation in supplemental materials.
10
EVOLUTION HEALTH: INNOVATIVE SOLUTIONS PROVIDER
FOR HEALTHCARES MOST CHALLENGING PATIENT POPULATIONS

Physician-Led Care Management - Solutions for High Risk Populations

Specializes in physician-led, population management High ROI Service Offerings

services in the post-acute, home, mobile environment

Focus on high risk, high cost and vulnerable populations with Comprehensive Population Assessment
advanced illness and multiple chronic conditions HRA, Mobile Diagnostics

Over 2,200 dedicated caregivers, and rapidly growing

Transitional Care
Leverages EmCare and AMR competencies and workforce In-Home Care, Facility Care, Virtual Support

Novel and clinically sophisticated Medical Command Center

providing healthcare logistics, care coordination,
Longitudinal High Risk Management
Home Based Primary Care, Co-Management
telemedicine, telemonitoring and remote care

Strong value proposition delivering on improving clinical Advanced Illness Management

outcomes and member/patient experience while reducing the Palliative Care, Hospice, Comfort Care
cost to risk-bearing entities

Key customer segments: health plans, health systems and at- 24/7 Unplanned Care
risk providers In-Home, Virtual and Mobile Clinic

Medical Command Center Services

Telemedicine, Telemonitoring, Telehealth

11
 EVOLUTION HEALTH: INTEGRATION DRIVEN
GROWTH WITH DEMONSTRATED MARKET TRACTION

Robust Clinical Care Model Strategic Deployment for Market Centricity

Integrated and Cross Selling with EmCare & AMR

Modular and Customizable Service Offerings

Innovative Partnership and JV Models

Risk Arrangements, Gain Sharing, Bundled Payments,

Capitation

Turnkey Outsourcing for Population Health Management

10% of Patients Account for More

Than 60% of Health Costs

Diverse and rapidly growing customer base

Strategic Innovation with Strong Market Traction and Recent Acceleration in Growth

12
RECENT EVENTS

Envisions 2015 Guidance:

Adjusted EBITDA of $653M-$665M and Adjusted EPS of $1.42 - $1.50
17 to 20 percent implied Adjusted EBITDA growth includes lost Medicaid parity revenue at ~80%
Adjusted EBITDA margin, to be fully offset by recent acquisitions at EmCares traditional margins

EmCare acquisition of Emergency Medical Associates, Scottsdale Emergency Associates

and VISTA Staffing Solutions completed in Q1 2015
Expected combined annual net revenues of approximately $435 million and 1.7 million annual
patient encounters
Envisions net leverage ratio 3.8x TTM Adjusted EBITDA at March 31, 2015

AMR entered a definitive agreement to acquire ambulance operations located in

northeastern U.S. with expected annual revenue of approximately $25M

Evolution Health joint venture with Ascension Health to complete phase-one roll out in
five markets by Spring 2015. Additional phases adding up to 18 more markets to be
completed over the next two years

Initial participation in Bundled Payment for Care Improvement (BPCI) initiative effective
July 1, 2015
13 Note: Adjusted EBITDA and Adjusted EPS are defined in Non-GAAP Financial Measures.
Financial Review
 STRONG HISTORICAL REVENUE AND EBITDA GROWTH

Net Revenue Adjusted EBITDA

05-14 CAGR: $ 600 05-14 CAGR:

3.4% $4,398 $ 575
6.9% $556
$ 550

$ 525

05-14 CAGR: $3,728 $ 500

05-14 CAGR:

$1,555
17.9% 25.8%

$193
$ 475

$446
$3,300
$ 450

$3,108
$ 425
$405

$1,369
$ 400

$2,859

$152
$ 375

$345
$2,570 $1,385

$144
$ 350

$322
$2,410
$1,441

$ 325

$287
$1,381

$126
$ 300

$2,107

$130
$ 275

$1,934 $247
$1,344

$1,799 $ 250
$1,402

$127
$ 225
$215
$1,219

$2,843 $183

$363
$132
$ 200
$1,189
$1,154

$96
$2,359

$ 175
$152

$294
$261
$1,915

$ 150

$98
$1,667

$219
$ 125
$1,478

$106

$192
$1,226

$ 159
$ 100
$1,008

$119

$115
$888

$ 75
$745
$645

$84
$ 50
$46
$ 25

$0

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
EmCare AMR
EmCare AMR

Long History of Consistent, Strong Revenue and Adjusted EBITDA Growth

Note: $ in millions. Adjusted EBITDA as defined in Non-GAAP Financial Measures. Prior periods have been adjusted accordingly for comparability purposes. See
reconciliation in supplemental materials. 2008 2014 net revenue CAGR is 10.6% and 2008 2014 Adjusted EBITDA CAGR is 14.5%.
15
 CONTINUED REVENUE AND EBITDA GROWTH IN 2015
Q1 2015 Financial Results Envision Q1 2015:
Revenue up 22.7%
Net Revenue Adjusted EBITDA Adjusted EBITDA up 16.3%
$1,245
EmCare
Revenue growth driven by:
$420

$1,014
$129 6.3% higher same-store volume,
including 7.5% higher ED volume
$370

$111 $101
Net new contract wins

$52
$35
$96
Acquisitions
$39

$33 $101
$35
$96
$33 Margin impacted by:
$825

$64 $72 Lower anesthesia collection rate

$644

Medicaid parity discontinued

$77
$72

$64 $72
AMR
Q2 2012 Q2 2013
Revenue growth driven by:
EmCare
Q2 2012
Q1 2014 Q1 2015
Q2 2013
Q1 2014 Q1 2015 7.8% higher same-market volume
EmCare AMR Margin expansion related to:
% Growth
EmCare 28.0%
AMR
% Margin
EmCare 11.1% 9.3%
Improved deployment
AMR 13.5% AMR 10.6% 12.3% Lower fuel costs
Envision 22.7% Envision 10.9% 10.4%

Continued Strong Performance in 2015

16 Note: $ in millions. Adjusted EBITDA as defined in Non-GAAP Financial Measures.
 INVESTMENT HIGHLIGHTS

Leading Player in Large and Growing Outsourced Healthcare Services Markets

Positioned at the Nexus of Rapidly Evolving Healthcare Landscape

Differentiated, Integrated Service Model Across the Patient Continuum

History of Strong Revenue and EBITDA Growth with Stable Cash Flows

Consistent Revenue and EBITDA Growth From Diversified Sources

Beneficiary of Healthcare Reform

Experienced Management Team with History of Success

17
Supplemental Materials
 ADJUSTED EBITDA RECONCILIATION
Q1 Q1
($ in millions) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2014 2015

$14.0 $39.1 $59.8 $84.8 $115.2 $131.7 $33.7 $41.2 $6.0 $24.8 $125.5 $33.4
Net income
(+) Depreciation and amortization
58.0 66.0 70.5 69.0 64.4 65.3 99.8 123.8 140.6 36.4 146.2 39.9
expense

1.8 6.4 2.2 - - - 6.5 14.1 5.7 0.8 7.0 -

(+) Restructuring charges
(+) Equity-based compensation
2.8 1.4 1.7 2.5 4.0 6.7 19.2 4.2 4.2 1.1 5.1 1.4
expense

- - - - - - - - - 0.8 5.0 3.1

(+) Transaction costs

- - - - - - - - - - - 1.7
(+) Severance and related costs

15.3 1.0 1.0 1.0 1.0 1.0 3.4 5.0 23.1 - - -

(+) Related party management fees 1
(+) Adjustment to net income (loss)
attributable to noncontrolling interest - - - - - - - - - - -2.3 -
due to deferred taxes

49.0 45.6 46.9 42.1 41.0 22.9 112.6 182.6 186.7 30.0 110.5 26.7
(+) Interest expense
(+) Realized (gain) loss on
0.2 0.5 -0.2 -2.7 -2.1 -2.5 - -0.4 -0.5 -0.6 -0.4 -
investments

-1.0 -2.3 -2.1 -2.1 -1.8 -1.0 32.0 -1.4 12.8 0.8 4.0 0.3
(+) Other expense (income), net

2.0 0.4 - 0.2 - 19.1 10.1 8.3 68.4 0.0 66.4 -

(+) Loss on early debt extinguishment

10.3 25 36.1 52.5 65.7 79.1 28.6 27.5 -1.0 16.7 89.5 22.5
(+) Income tax expense (benefit)
(+) Equity in earnings of
-0.1 -0.4 -0.8 -0.3 -0.3 -0.3 -0.4 -0.4 -0.3 0.0 -0.3 -0.1
unconsolidated subsidiary

$152.3 $182.5 $215.2 $247.1 $287.0 $322.1 $345.4 $404.5 $445.7 $110.8 $556.2 $128.9
Reported Adjusted EBITDA

9.7
Prior Period Insurance Case Reserve
$152.3 $182.5 $215.2 $247.1 $287.0 $322.1 $345.4 $404.5 $455.4 $110.8 $556.2 $128.9
Pro Forma Adjusted EBITDA

19 1. 2005 related party management fees represent both Laidlaw and Onex management fees and 2013 includes $20M to terminate the CD&R consulting
agreement